2024 earnings way below expectations; outlook remains challenging

PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE MORE REPORTS FROM BLOOMBERG: RESP CMBR <GO> OR http://www.cmbi.com.hk 1 MN 21 Apr 2025 CMB International Global Markets | Equity Research | Company Update Zhejiang Dingli (603338 CH) 2024 earnings way below expectations; outlook remains challenging Zhejiang Dingi’s (Dingi) net profit in 2024 came in at RMB1.63bn (-13% YoY), substantially falling short of our/Bloomberg consensus by 20%/21%. The negative surprise was due to: (1) advanced shipments of AWPs to the US warehouses for customs clearance in 4Q24 to avoid upcoming tariff hikes, which in turn resulted in early recognition of some costs; (2) the acquisition of CMEC in mid-2024 that resulted in the consolidation of higher salary and warehouse expenses. During the post-results call, Dingli revealed that the current AWP inventory (not subject to the recent increase in tariff) will be enough to cover the sales in the US until Sep 2025. We maintain our view that the unpredictable US tariff policy will (1) hurt the demand for AWPs in the US; and (2) put Dingli into a quandary given the high proportion of capacity in China serving the US market. We revise down our 2025E-26E earnings forecast by 13%, due to higher cost assumptions. Maintain HOLD with new TP of RMB44 (previously RMB51), based on an unchanged 12x 2025E P/E (derived from 1SD below the three-year average P/E of 13.5x to reflect earnings slowdown).  4Q24 results highlights. Dingli’s gross profit dropped 28% to RMB515mn in 4Q24, due to a weak revenue growth (+6% YoY) and a 14.9ppt YoY contraction of gross margin (to 30.9%). Net profit plummeted 71% YoY to RMB168mn, due to a higher administrative expense ratio (+2.3ppt YoY), an increase in asset impairment and share of JV loss that offset the increase in other gains.  Measures to mitigate tariff impact. The US was the largest source of revenue in 2024 (30% of the total). Dingli’s current inventory of AWPs in the US (not subject to Trump’s newly proposed tariff) is enough to cover sales until Sep 2025. Going forward, Dingli will likely pass through part of the tariff by raising ASP. Besides, in the case of a high level of tariff for a prolonged period, Dingli will expand the production capacity in the US, despite a much higher production cost compared with China.  Upside risks: (1) Substantial reduction of proposed tariff on China; (2) stronger-than-expected demand in other countries that offsets the weakness in the US.  Downside risks: (1) Further increase in tariffs in the US; (2) further intensified competition in China’s AWP market; (3) continuous weakness of overseas demand. Target Price RMB44.00 (Previous TP RMB51.00) Up/Downside 11.4% Current Price RMB39.48 China Capital Goods Wayne FUNG, CFA (852) 3900 0826 waynefung@cmbi.com.hk Stock Data Mkt Cap (RMB mn) 19,988.7 Avg 3 mths t/o (RMB mn) 387.3 52w High/Low (RMB) 72.98/39.48 Total Issued Shares (mn) 506.3 Source: FactS

立即下载
传统制造
2025-04-21
招银国际
Wayne Fung
6页
1.13M
收藏
分享

[招银国际]:2024 earnings way below expectations; outlook remains challenging,点击即可下载。报告格式为PDF,大小1.13M,页数6页,欢迎下载。

本报告共6页,只提供前10页预览,清晰完整版报告请下载后查看,喜欢就下载吧!
立即下载
本报告共6页,只提供前10页预览,清晰完整版报告请下载后查看,喜欢就下载吧!
立即下载
水滴研报所有报告均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
相关图表
图表 43 相关公司估值
传统制造
2025-04-21
来源:合成生物深度系列报告之一:以生物造万物,构建AI+新质生产力新业态
查看原文
图表 42 公司在菌种筛选及优化领域拥有数项国内领先技术成果
传统制造
2025-04-21
来源:合成生物深度系列报告之一:以生物造万物,构建AI+新质生产力新业态
查看原文
图表 41 公司纤维素酶产品可为纺织行业降本
传统制造
2025-04-21
来源:合成生物深度系列报告之一:以生物造万物,构建AI+新质生产力新业态
查看原文
图表 39 Bota Bio 融资历程
传统制造
2025-04-21
来源:合成生物深度系列报告之一:以生物造万物,构建AI+新质生产力新业态
查看原文
图表 38 弈柯莱依照合成生物学研发逻辑建立 4 个实验室技术创新平台
传统制造
2025-04-21
来源:合成生物深度系列报告之一:以生物造万物,构建AI+新质生产力新业态
查看原文
图表 37 2021 年弈柯莱已具备多项医药类产品产能
传统制造
2025-04-21
来源:合成生物深度系列报告之一:以生物造万物,构建AI+新质生产力新业态
查看原文
回顶部
报告群
公众号
小程序
在线客服
收起